LIMN
Income statement / Annual
Last year (2024), Liminatus Pharma, Inc. Class A Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Liminatus Pharma, Inc. Class A Common Stock's net income was -$2.90 M.
See Liminatus Pharma, Inc. Class A Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$1.85 M
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$856.00 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.91 M
|
$2.59 M
|
$856.00 K
|
$2.53 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.91 M
|
$2.59 M
|
$2.71 M
|
$2.53 M
|
| Cost And Expenses |
$2.91 M
|
$2.59 M
|
$2.71 M
|
$2.53 M
|
| Interest Income |
$137.72 K
|
$10.00 K
|
$0.00
|
$16.84 K
|
| Interest Expense |
$138.10 K
|
$175.00 K
|
$219.00 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$2.75 M |
-$1.09 M |
-$2.71 M |
$4.37 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$20.86 K
|
$1.39 M
|
-$219.00 K
|
$6.90 M
|
| Income Before Tax |
-$2.89 M
|
-$1.19 M
|
-$2.93 M
|
$4.37 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$18.84 K
|
$33.99 K
|
$0.00
|
$0.00
|
| Net Income |
-$2.90 M
|
-$1.23 M
|
-$2.93 M
|
$4.37 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.4 |
-0.15 |
0.3 |
0.13 |
| EPS Diluted |
-0.4 |
-0.15 |
0.3 |
0.13 |
| Weighted Average Shares Out |
$7.19 M
|
$8.01 M
|
$34.43 M
|
$34.50 M
|
| Weighted Average Shares Out Diluted |
$7.19 M
|
$8.01 M
|
$34.43 M
|
$34.50 M
|
| Link |
|
|
|
|
